Christopher Astle
Insider
First SEC filing: Jan. 6, 2023 · Latest: Jan. 6, 2023
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net: $0
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Jan. 8, 2024 | ZYME | S | 1,431 | $11.22 | $16,056 | 6,503 Direct | -18.04% | Disposed | 124.2% (price as of 2026-10-02) |
| Jan. 5, 2024 | ZYME | A | 30,000 | · | · | 30,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | ZYME | A | 50,000 | · | · | 50,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2024 | ZYME | M | 10,500 | · | · | 21,000 Direct | -33.33% | Disposed | (price as of 2026-10-02) |
| Jan. 5, 2024 | ZYME | S | 4,563 | $10.65 | $48,596 | 7,934 Direct | -36.51% | Disposed | 136.2% (price as of 2026-10-02) |
| Jan. 5, 2024 | ZYME | M | 10,500 | · | · | 12,497 Direct | +525.79% | Acquired | (price as of 2026-10-02) |
| Dec. 11, 2023 | ZYME | M | 1,550 | · | · | 0 Direct | -100.00% | Disposed | (price as of 2026-10-02) |
| Dec. 11, 2023 | ZYME | S | 886 | $9.13 | $8,089 | 1,997 Direct | -30.73% | Disposed | 175.5% (price as of 2026-10-02) |
| Dec. 11, 2023 | ZYME | M | 1,550 | · | · | 2,883 Direct | +116.28% | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2023 | ZYME | A | 31,500 | · | · | 31,500 Direct | · | Acquired | (price as of 2026-10-02) |
| Jan. 5, 2023 | ZYME | A | 47,000 | · | · | 47,000 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 12, 2022 | ZYME | M | 1,550 | · | · | 1,550 Direct | -50.00% | Disposed | (price as of 2026-10-02) |
| Dec. 12, 2022 | ZYME | S 10b5-1 | 887 | $6.01 | $5,331 | 1,333 Direct | -39.95% | Disposed | 318.5% (price as of 2026-10-02) |
| Dec. 12, 2022 | ZYME | M | 1,550 | · | · | 2,220 Direct | +231.34% | Acquired | (price as of 2026-10-02) |
| Dec. 12, 2022 | ZYME | M | 1,550 | · | · | 1,550 Direct | -50.00% | Disposed | (price as of 2026-10-02) |
| Dec. 12, 2022 | ZYME | S 10b5-1 | 887 | $6.01 | $5,331 | 1,333 Direct | -39.95% | Disposed | 318.5% (price as of 2026-10-02) |
| Dec. 12, 2022 | ZYME | M | 1,550 | · | · | 2,220 Direct | +231.34% | Acquired | (price as of 2026-10-02) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Jan. 5, 2024 | ZYME | Restricted Stock Unit | Common Stock | · | · | 30,000 | Acquired |
| Jan. 5, 2024 | ZYME | Stock Option (Right to Buy) | Common Stock | $10.56 | Jan. 4, 2034 | 50,000 | Acquired |
| Jan. 5, 2024 | ZYME | Restricted Stock Unit | Common Stock | · | · | 10,500 | Disposed |
| Dec. 11, 2023 | ZYME | Restricted Stock Unit | Common Stock | · | · | 1,550 | Disposed |
| Jan. 5, 2023 | ZYME | Restricted Stock Unit | Common Stock | · | · | 31,500 | Acquired |
| Jan. 5, 2023 | ZYME | Stock Option (Right to Buy) | Common Stock | $8.00 | Jan. 4, 2033 | 47,000 | Acquired |
| Dec. 12, 2022 | ZYME | Restricted Stock Unit | Common Shares | · | · | 1,550 | Disposed |
| Dec. 12, 2022 | ZYME | Restricted Stock Unit | Common Shares | · | · | 1,550 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $410,093 | · | · | · | $124,895 | · | $147,230 | $1,191,820 |
| 2022 | $358,749 | · | · | · | $203,048 | · | $159,436 | $1,315,005 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.